1. Home
  2. NCEL vs MBAI Comparison

NCEL vs MBAI Comparison

Compare NCEL & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NCEL

NewcelX Ltd. Ordinary Shares

N/A

Current Price

$2.64

Market Cap

12.0M

Sector

Health Care

ML Signal

N/A

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

N/A

Current Price

$1.59

Market Cap

10.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
NCEL
MBAI
Founded
2008
2004
Country
Switzerland
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.0M
10.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NCEL
MBAI
Price
$2.64
$1.59
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
186.8K
7.2M
Earning Date
12-01-2025
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.89
$0.59
52 Week High
$7.64
$3.92

Technical Indicators

Market Signals
Indicator
NCEL
MBAI
Relative Strength Index (RSI) 49.64 45.20
Support Level $2.40 $1.31
Resistance Level $2.86 $1.58
Average True Range (ATR) 0.24 0.44
MACD 0.04 -0.05
Stochastic Oscillator 38.55 8.24

Price Performance

Historical Comparison
NCEL
MBAI

About NCEL NewcelX Ltd. Ordinary Shares

NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: